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SIGNIFICANCE
Psoriasis is a common chronic inflammatory skin disorder 
that can also affect the nails. It develops during childhood 
in almost one-third of cases. Early identification of children 
with an increased risk for a severe course of their psoria-
sis is essential for adequate intervention and subsequent 
limitation of disease progression. This study shows that 
nail involvement in paediatric psoriasis is associated with a 
more severe psoriasis disease course during 2-year follow-
up. These findings suggest that nail psoriasis is a poten-
tial clinical predictor for a more severe disease course over 
time in children with psoriasis. 
Little is known about the relationship between nail 
psoriasis and psoriasis severity in children, and there 
has been no longitudinal assessment of psoriasis seve-
rity related to nail psoriasis. The aim of this study was 
to assess whether nail psoriasis could serve as a pre-
dictor for a more severe disease course. De-identified 
data were obtained from the ChildCAPTURE registry, a 
daily clinical practice cohort of children with psoriasis, 
from September 2008 to November 2015. Cross-sec-
tional analyses were performed at baseline. Longitudi-
nal data until 2-year follow-up were analysed by linear 
mixed models. Nail psoriasis was present in 19.0% of 
all 343 patients at baseline and cross-sectionally as-
sociated with higher Psoriasis Area and Severity Index 
(PASI) (p = 0.033). Longitudinal analysis demonstra-
ted higher PASI (p < 0.001) during 2-year follow-up in 
patients with nail involvement at baseline. These fin-
dings suggest that nail psoriasis is a potential clinical 
predictor for more severe disease course over time in 
paediatric psoriasis.
Key words: paediatric psoriasis; pediatric psoriasis; nail psoria-
sis; psoriasis severity.
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Psoriasis develops during childhood in almost one-third of cases, with an almost linear increase in pre-
valence rates until 18 years of age (1–5). Nail psoriasis 
affects over 50% of the adult population with psoriasis, 
and is even more prevalent in patients with psoriatic 
arthritis (PsA) (6–11). Although a range of prevalence 
rates has been reported in children, a recent study of 
4,853 children revealed an overall prevalence of 15.7% 
(12, 13). 
Evidence regarding nail psoriasis in children and its 
association with psoriasis severity is scarce. A recent 
multicentre, cross-sectional study demonstrated more 
severe disease in 313 children with nail involvement 
compared with those without nail involvement. Nail 
psoriasis was also associated with male sex, palmoplantar 
psoriasis and PsA (14). Two other cross-sectional studies 
in children reported no relationship between nail psoria-
sis and psoriasis severity (13, 15). Remarkably, reported 
signs of nail psoriasis and psoriasis severity scores 
in these studies were based on historical information 
rather than physical examination of the nails and skin. In 
adults, studies have found nail psoriasis to be a potential 
clinical predictor of developing enthesitis and PsA (16, 
17), and have demonstrated an association between nail 
psoriasis and higher psoriasis severity scores (9, 18–21). 
Augustin et al. (20) reported higher Psoriasis Area and 
Severity Index (PASI) and Body Surface Area (BSA) 
scores in adult patients with nail psoriasis in a cohort of 
3,531 patients. Based on these findings, they proposed to 
examine whether current nail involvement is predictive 
of a more severe psoriasis course in future.
Approximately one-third of children with psoriasis 
experience more severe or recalcitrant disease (5, 22). 
Early identification of children with an increased risk for 
a severe disease course is essential for adequate interven-
tion and subsequent limitation of disease progression. 
The presence of nail psoriasis as non-invasive, clinical 
predictor for a more severe disease course could contri-
bute to this concept and become important for providing 
optimal treatment strategies.
The aim of this prospective, observational study in a 
daily practice cohort of paediatric patients with psoriasis 
was to describe epidemiological and disease characteris-
tics of children diagnosed with nail psoriasis at baseline, 
to determine the presence of nail psoriasis over time, to 
assess the relationship between nail psoriasis and repor-
ted psoriasis severity scores, and, ultimately, to study 
the predictive value of nail psoriasis for a more severe 
disease course over time.
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MATERIALS AND METHODS 
Patient selection and study design
This prospective, single-centre study was conducted in children 
(aged < 18 years) diagnosed with psoriasis who attended the outpa-
tient clinic of the Department of Dermatology at the Radboud Uni-
versity Medical Center between September 2008 and November 
2015. All available data were extracted from the ChildCAPTURE 
registry (Continuous Assessment of Psoriasis Treatment Use 
Registry), a prospective, long-term, observational daily practice 
cohort of children with psoriasis. The study was carried out in the 
Netherlands in accordance with the applicable rules concerning 
the review of research ethics committees and informed consent. 
Data collection and management
At baseline and during follow-up, patient, psoriasis and treatment 
characteristics, including presence of nail psoriasis and PsA, were 
collected using a standard case report form. Psoriasis severity 
scores (PASI, BSA and Physician Global Assessment (PGA)) and 
patient-reported outcome measures (Children’s Dermatology Life 
Quality Index (CDLQI); visual analogue scales (VAS) for psoria-
sis severity, itch, pain and fatigue) were also collected. Patients 
on topical treatment were seen at least every 6 months to 1 year; 
patients on systemic medication (e.g. methotrexate, dimethyl-
fumarate, biologics) were seen every 3 months. Cross-sectional 
analyses were performed at baseline visit.
Nail psoriasis. The diagnosis of nail psoriasis was made by 2 
clinicians, and exclusively based on physical examination. All 
20 nails were examined. Furthermore, the target Nail Psoriasis 
Severity Index (NAPSI) was used as a quantitative nail assess-
ment tool at baseline and during each follow-up visit. This tool 
divides the nail into imaginary quadrants and records the number 
of quadrants in which any manifestations of nail matrix psoriasis 
(pitting, leukonychia, red spots in lunula, nail plate crumbling) or 
nail bed psoriasis (oil drop discoloration, onycholysis, nail bed 
hyperkeratosis, splinter haemorrhage) are present. At each visit the 
most severely affected nail was assigned a nail matrix and nail bed 
score of 0–4, which yielded a composite score between 0 and 8. 
Psoriasis severity scores. PASI, BSA and PGA scores from 0 
(clear) to 5 (very severe) were reported at baseline and during 
each follow-up visit. All psoriasis severity scores over a period of 
up to 2 years were included to assess disease severity over time in 
patients with and without nail involvement. This timeframe was 
based on mean ± standard deviation (SD) follow-up duration of 
22.9 ± 23.5 months in 343 children. Two-year follow-up data were 
available for 40.5% of children. The percentage of patients with at 
least 2-year follow-up was comparable between the groups (nail 
psoriasis 41.5%; no nail psoriasis 40.3%, p = 0.853).
Presence of nail psoriasis over time
The presence or absence of nail psoriasis during follow-up was 
captured to better understand its consistence over time in children. 
The following categories can be distinguished: (i) patients with 
persistent nail psoriasis over time, (ii) patients with nail psoriasis 
occasionally during follow-up, and (iii) patients without nail 
psoriasis at any point in time.
Statistical analysis
Cross-sectional. Demographic data were summarized as medians 
and interquartile ranges (IQR) for continuous variables, and num-
bers and percentages for categorical variables. Patient and disease 
characteristics were presented for: (i) total number of patients, (ii) 
patients with nail involvement at baseline, and (iii) patients without 
nail involvement at baseline. Medians reported in patients with 
and without nail psoriasis were compared by Mann–Whitney U 
test. Differences between groups with regard to frequencies were 
analysed by χ2 tests for independence. 
Longitudinal. PASI and PGA scores over time were both studied 
using linear mixed models (LMM). Psoriasis severity score 
was defined as dependent variable, and time (in months) from 
baseline visit as one of the main independent variables to model 
psoriasis severity over time. The occurrence of nail psoriasis 
at baseline and the interaction term between time and nail 
psoriasis were other key independent variables. The latter was 
included to test whether psoriasis severity scores over time are 
different between patients with vs. without nail involvement at 
baseline. Sex, psoriasis severity at baseline, psoriasis duration, 
Fig. 1. Estimated psoriasis severity scores during 2-year follow-up 
in paediatric psoriasis patients with nail involvement (n = 65) and 
without nail involvement (n = 278) at baseline. (A) Mean Psoriasis 
Area and Severity Index (PASI) score during 2-year follow-up. (B) Mean 
Physician Global Assessment (PGA) score during 2-year follow-up. Linear 
mixed models were used to predict PASI and PGA scores over time. In 
both models sex, psoriasis duration and severity scores at baseline were 
incorporated as possible confounders.
(Graphs were presented for female subjects with a psoriasis duration of 
24 months, a PASI score at baseline of 6.4 and 8.6 for subjects with and 
without nail psoriasis, respectively, and a PGA score at baseline of 2.43 
and 2.75, respectively. Most intensive treatment received until first visit, 
concomitant anti-psoriatic treatment, presence of nail matrix involvement, 
presence of nail bed involvement and presence of nail psoriasis over 
time did not alter the unadjusted exposure-outcome effect by ≥10% and 
were therefore not kept in the model. Mean severity scores at 24 months 
were incorporated in our linear mixed model, but could not be presented 
graphically due to lower numbers at this point.).
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most intensive treatment received until first visit, concomitant 
anti-psoriatic treatment, presence of nail matrix involvement, 
presence of nail bed involvement, and presence of nail psoriasis 
over time, were incorporated as possible confounding factors. 
Confounders that altered the unadjusted exposure-outcome effect 
by ≥ 10% were kept in the model. Variance components were 
used as covariance type (default setting of SPSS). As a result of 
this model, psoriasis severity scores over time for patients with 
nail psoriasis vs. without nail psoriasis at baseline were shown 
in Fig. 1. Corresponding estimated marginal means (EMM) 
were also calculated. In case the difference in EMM reaches 
significance, psoriasis severity scores over time are different 
between the 2 groups. 
Statistical package SPSS version 22.0 (IBM, Armonk, NY, 
USA) was used to perform all analyses. p < 0.05 was considered 
significant. 
RESULTS 
Patient characteristics
Data from 343 de-identified patients were extracted from 
the ChildCAPTURE registry. Patient characteristics at ba-
seline are shown in Table I. The majority of patients were 
females (58.0%) and median age and psoriasis duration 
were 11.0 and 1.4 years, respectively. Plaque psoriasis was 
the most common type of psoriasis (88.6%). Median PASI, 
BSA and PGA scores at first consultation were, respecti-
vely, 5.8, 5.4 and 2.0. Patients reported a median CDLQI 
score of 8.0. Koebnerization was observed in 78 (25.8%) 
patients. At baseline, 0.3% of patients were diagnosed 
with PsA and 3.2% had arthralgia without clinical arthritis. 
Table I. Characteristics of paediatric psoriasis patients with and without nail involvement at baseline (n = 343)
Characteristics
Total 
(n = 343)
Patients with nail involvement 
(n = 65, 19.0%)
Patients without nail involvement 
(n = 278, 81.0%) p-value
Sex, n (%) 0.015
  Male 144 (42.0) 36 (55.4) 108 (38.8)
  Female 199 (58.0) 29 (44.6) 170 (61.2)
Family history, n (%)
  Psoriasis in parents or siblings 112 (32.7) 20 (30.8) 92 (33.1) 0.719
  Psoriatic arthritis in parents or siblings     4 (1.2)   1 (1.5)   3 (1.1) 0.756
Psoriasis trigger (n = 340), n (%) 0.647
  No trigger 228 (66.5) 45 (70.3) 183 (66.3)
  Infection 53 (15.5)   8 (12.5) 45 (16.3)
  Stress 47 (13.7) 10 (15.6) 37 (13.4)
  Othera 12 (3.5)   1 (1.6) 11 (4.0)
Koebner phenomenon (n = 302)b, n (%) 78 (25.8) 18 (31.0) 60 (24.6) 0.314
Joint involvement, n (%) 0.887
  PsA     1 (0.3)   0 (0)   1 (0.4)
  Arthralgiac 11 (3.2)   2 (3.1)   9 (3.2)
  No PsA or arthralgia 331 (96.5) 63 (96.9) 268 (96.4)
Type of psoriasisd
  Plaque 304 (88.6) 57 (87.7) 247 (88.8) 0.791
  Guttate 62 (18.1) 13 (20.0) 49 (17.6) 0.654
  Pustular   6 (1.7)   3 (1.1)   3 (4.6) 0.050
  Palmoplantar   5 (1.5)   5 (7.7)   0 (0) 0.000
  Scalp 298 (86.9) 57 (87.7) 241 (86.7) 0.829
  Inverse 150 (43.7) 29 (44.6) 121 (43.5) 0.873
Type of nail involvement (n = 64), n (%)
Nail matrix involvement 53 (82.8)
Nail bed involvement 27 (42.2)
Most intensive treatment received (n = 242) 0.026
  Topical or intense topicale 219 (63.8) 42 (82.4) 177 (92.7)
  Systemic treatment 23 (6.7)   9 (17.6) 14 (7.3)
Age, years, median (IQR) 11.0 (7.0) 11.0 (4.0) 10.0 (7.0) 0.232
Psoriasis duration, years, median (IQR)   1.4 (3.6)   1.8 (4.9)   1.2 (3.6) 0.047
Psoriasis severity at baseline (n = 340), median (IQR)
  PGA 2.0 (1.0)   3.0 (2.0)   2.0 (1.0) 0.035
  PASI 5.8 (5.0)   6.5 (6.1)   5.6 (4.7) 0.033
  BSA 5.4 (8.6)   7.0 (13.8)   5.0 (8.1) 0.034
Target NAPSI (0–8), median (IQR)f   4.0 (2.0)
CDLQI (0-30; n = 328), median (IQR) 8.0 (7.0)   9.0 (8.0)   7.0 (7.0) 0.098
DLQI (0-30; n = 25), median (IQR) 8.0 (6.0) 12.0 (5.0)   7.0 (6.0) 0.101
VAS, median (IQR)
  Psoriasis severity (n = 192) 57.5 (39.0) 51.0 (44.0) 58.0 (39.0) 0.734
  Itch (n = 258) 45.5 (49.0) 42.0 (65.0) 47.0 (45.0) 0.724
  Pain (n = 258)   5.0 (25.0)   9.0 (53.0)   3.5 (20.0) 0.030
  Fatigue (n = 256) 10.0 (40.0) 10.0 (41.0) 10.0 (40.0) 0.916
aThese included primarily trauma or surgical procedures. bPositive Koebner phenomenon was defined as having an isomorphic response regularly or often. cArthralgia 
was defined as aching or pain in the joints without true arthritis. dTotal number of patients does not equal sum of patients reporting different types of psoriasis because 
more than one type of psoriasis can be reported in the same patient. eIntense topical treatment included dithranol treatment or ultraviolet B (UVB) phototherapy. fThe 
NAPSI score for most severely affected nail was calculated if nail psoriasis was present.
BSA: body surface area; CDLQI: Children’s Dermatology Life Quality Index; DLQI, Dermatology Life Quality Index; NAPSI: Nail Psoriasis Severity Index; PASI: Psoriasis 
Area and Severity Index; PGA: Physician’s Global Assessment; PsA: psoriatic arthritis. Significant values (p < 0.05) are shown in bold.
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Nail psoriasis is associated with male sex, higher pain 
score and more severe disease at baseline
A total of 65 subjects (19.0%) presented with nail 
psoriasis at their first visit (Table I). The median target 
NAPSI was 4.0. Nail psoriasis was associated with male 
sex (p = 0.015), concomitant higher VAS pain score 
(nail psoriasis 9.0 (53.0); no nail psoriasis 3.5 (20.0), 
p = 0.030) and more severe psoriasis. Median PASI sco-
res in patients with and without nail involvement were, 
respectively, 6.5 (6.1) and 5.6 (4.7) (p = 0.033). BSA (nail 
psoriasis 7.0 (13.8); no nail psoriasis 5.0 (8.1), p = 0.034) 
and PGA (nail psoriasis 3.0 (2.0); no nail psoriasis 2.0 
(1.0), p = 0.035) scores were also higher in patients with 
nail psoriasis. Psoriasis patients with nail involvement 
more often received systemic treatment at any time be-
fore their first visit (17.6 % in patients with nail psoriasis 
vs. 7.3% in patients without nail psoriasis, p = 0.026). 
All patients with palmoplantar psoriasis (n = 5) had nail 
psoriasis. Although total CDLQI score was slightly 
higher in patients with nail involvement, this effect did 
not reach statistical significance (p = 0.098). Number 
of patients with a positive Koebner phenomenon was 
similar between the 2 groups.
The presence of nail psoriasis during total available 
follow-up of all patients (n = 343; mean follow-up dura-
tion 22.9 months ± 23.6) was also captured. In total, 8.2% 
of patients had persistent nail psoriasis over time, and 
22.1% occasionally had nail psoriasis. Most patients 
(69.7%) did not show signs of nail psoriasis at any time.
Nail psoriasis predicts a more severe disease course 
during follow-up
Longitudinal analysis of psoriasis severity scores in 
patients with and without nail psoriasis at baseline was 
performed to further investigate the role of nail psoria-
sis as predictor for a more severe disease course over 
time. LMM demonstrated an overall higher PASI score 
during 2-year follow-up in children with nail psoriasis 
compared with children without nail psoriasis at baseline 
(nail psoriasis at baseline, EMM 5.73 (95% confidence 
interval (CI) 5.00–6.46); no nail psoriasis at baseline, 
EMM 4.17 (95% CI 3.80–4.53), p < 0.001). This was 
also true for PGA scores during follow-up (nail psoria-
sis at baseline, EMM 2.55 (95% CI 2.35–2.76); no nail 
psoriasis at baseline, EMM 1.84 (95% CI 1.74–1.94), 
p < 0.001). Psoriasis severity scores over time are shown 
Table II. Linear mixed model used to estimate PASI scores during 
2-year follow-up in paediatric psoriasis patients with (n = 65) and 
without (n = 278) nail involvement at baseline
Variable Estimate 95% CI p-value
Intercept 1.93   0.23–3.64 0.000
Sex 0.688
  Male 0.13 –0.50–0.75
  Female 0a
Nail psoriasis at baseline 0.000
  No 0.20 –1.60–1.99
  Yes 0a
Time from baseline visit 0.000
  3 months 2.86   1.17–4.54
  6 months 0.49 –1.30–2.29
  9 months 0.95 –0.85–2.75
  12 months 2.78   0.86–4.68
  15 months 0.26 –1.62–2.13
  18 months 1.44 –0.50–3.38
  21 months 0.25 –1.70–2.20
  24 months 0a
Psoriasis duration,  months 0.11   0.00–0.21 0.047
PASI at baseline 0.28   0.22–0.33 0.000
Interaction term between nail psoriasis at baseline visit and time 
from baseline visit
0.015
  Nail psoriasis at baseline visit=no
  Time from baseline visit=3 months
–2.44 –4.37 to 
–0.50
  Nail psoriasis at baseline visit=no
  Time from baseline visit=6 months
–0.89 –2.95–1.17
  Nail psoriasis at baseline visit=no
  Time from baseline visit=9 months
–1.74 –3.83–0.34
  Nail psoriasis at baseline visit=no
  Time from baseline visit=12 months
–3.85 –6.04 to 
–1.66
  Nail psoriasis at baseline visit=no
  Time from baseline visit=15 months
–1.65 –3.84–0.54
  Nail psoriasis at baseline visit=no
  Time from baseline visit=18 months
–2.37 –4.63 to 
–0.11
  Nail psoriasis at baseline visit=no
  Time from baseline visit=21 months
–1.12 –3.40–1.16
  Nail psoriasis at baseline visit=no
  Time from baseline visit=24 months
  0a
aThis parameter is set to zero because it is redundant.
CI: confidence interval; PASI: Psoriasis Area and Severity Index.
Table III. Linear mixed model used to estimate PGA scores during 
2-year follow-up in paediatric psoriasis patients with (n = 65) and 
without (n = 278) nail involvement at baseline
Variable Estimate 95% CI p-value
Intercept 1.22   0.74–1.70 0.000
Sex 0.616
  Male 0.04 –0.13–0.22
  Female 0a
Nail psoriasis at baseline 0.000
  No –0.03 –0.49–0.43
  Yes   0a
Time from baseline visit 0.024
  3 months 0.38 –0.04–0.80
  6 months 0.61 0.16–1.06
  9 months 0.58 0.13–1.03
  12 months 1.25 0.78–1,72
  15 months 0.51 0.04–0.97
  18 months 0.49 0.01–0.97
  21 months 0.28 –0.20–0.77
  24 months 0a
Psoriasis duration, months 0.04 0.01–0.06 0.013
PGA at baseline 0.25 0.17–0.34 0.000
Interaction term between nail psoriasis at baseline visit and time from 
baseline visit
0.000
  Nail psoriasis at baseline visit=no
  Time from baseline visit=3 months
–0.35 –0.84–0.13
  Nail psoriasis at baseline visit=no
  Time from baseline visit=6 months
–0.81 –1.32 to –0.29
  Nail psoriasis at baseline visit=no
  Time from baseline visit=9 months
–0.83 –1.35 to –0.31
  Nail psoriasis at baseline visit=no
  Time from baseline visit=12 months
–1.53 –2.08 to –0.99
  Nail psoriasis at baseline visit=no
  Time from baseline visit=15 months
–0.89 –10.44 to –0.35
  Nail psoriasis at baseline visit=no
  Time from baseline visit=18 months
–0.68 –10.24 to –0.12
  Nail psoriasis at baseline visit=no
  Time from baseline visit=21 months
–0.36 –0.93–0.21
  Nail psoriasis at baseline visit=no
  Time from baseline visit=24 months
  0a
aThis parameter is set to zero because it is redundant.
CI: confidence interval; PGA: Physician’s Global Assessment.
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in Fig. 1. Results were corrected for possible confoun-
ders at baseline, including sex, psoriasis duration and 
psoriasis severity score at baseline. Most intensive treat-
ment received until first visit, concomitant anti-psoriatic 
treatment, presence of nail matrix involvement, presence 
of nail bed involvement and presence of nail psoriasis 
over time did not alter the unadjusted exposure-outcome 
effect and were therefore not kept in the model. Tables 
II and III provide detailed information about the mo-
dels used.
DISCUSSION 
This single-centre, prospective study focused on the 
occurrence of nail involvement in paediatric psoriasis, 
epidemiological and clinical characteristics of this sub-
population, and its predicting value for a more severe 
disease course. Whereas conflicting results were previ-
ously reported in children, we found higher psoriasis 
severity scores in children with nail psoriasis within a 
large paediatric psoriasis population, both at baseline 
and during follow-up. Pourchot et al. (14) also reported 
more severe skin disease in children with nail psoriasis. 
However, psoriasis severity was defined as the use of 
systemic medication before or at the day of inclusion 
and not determined by physical examination. Mercy 
et al. (13) did not find an association between nail in-
volvement and severity of skin psoriasis in 181 children 
aged 5–17 years, but reported that a greater proportion 
of children with severe psoriasis had a history of nail 
involvement (severe psoriasis 43.7% vs. mild psoriasis 
33.3%, p = 0.300). Previous studies in children also 
demonstrated nail psoriasis to be present more often in 
boys than girls, suggesting a possible role for koebner-
ization in boys (13, 14). Nail psoriasis in our population 
was also present more frequently in boys than in girls. 
However, no association was found between the Koebner 
phenomenon and male sex by an additional χ2 test for 
independence (p = 0.580). Pourchot et al. (14) found a 
significant association between nail psoriasis and PsA 
(p = 0.03) in children with psoriasis. The current study 
did not demonstrate an association between nail psoriasis 
and joint involvement. However, it should be noted that 
only one patient (0.3%) was diagnosed with PsA in our 
population at baseline.
Cross-sectional analyses at baseline found nail pso-
riasis to be present in 19.0% of children. Piraccini et al. 
(12) reported an overall prevalence of 15.7% in 4,853 
children and, respectively, 19.4% and 15.5% in 2 centres 
specialized in nail disorders in Greece and Italy. Preva-
lence rates in adult psoriasis are higher, which suggests 
an association with psoriasis duration, but this is still a 
matter of debate (18, 20, 21). In our population, no sig-
nificant difference in psoriasis duration between patients 
with vs. without nail involvement was found. Moreover, 
almost 80% of children reported either persistent nail 
psoriasis (8.2%) or no signs of nail psoriasis (69.7%) 
during total follow-up. From a clinical perspective, the 
latter also suggests the presence of nail psoriasis to be a 
relatively stable process rather than a highly fluctuating 
on-off phenomenon in children. This, together with our 
finding that presence of nail psoriasis over time did not 
affect psoriasis severity scores over time, advocates nail 
psoriasis at baseline as a representative point in time to 
distinguish between having or not having nail psoriasis 
and assess its predictive value for a more severe disease 
course until 2-year follow-up. 
This study is the first to show the role of nail psoriasis 
at baseline as a non-invasive predictor for a more severe 
disease course over time. Longitudinal analysis was cor-
rected for possible confounders at baseline, including 
sex, psoriasis duration and psoriasis severity score at 
baseline. The results revealed substantially higher PASI 
and PGA scores during 2-year follow-up in children 
with clinical signs of nail psoriasis at baseline. As such, 
our longitudinal findings go beyond previously reported 
cross-sectional findings in both children and adults, and 
fit within the concept of early identification of patients 
at risk for a more severe disease course. Our study was 
limited by the use of the target NAPSI (0–8), in which 
only the most severely affected nail was scored. Further 
research using specific and validated nail psoriasis sco-
ring systems of all fingernails and/or toenails is needed 
to further determine the role of different signs of nail 
psoriasis and the extent of nail involvement in predicting 
the severity of skin psoriasis.
Mean follow-up duration of all children in our re-
gistry was approximately 2 years at time of analysis, 
limiting longitudinal analysis and the subsequent role of 
nail psoriasis in predicting psoriasis severity to 2-year 
follow-up. Whether nail psoriasis is predictive for more 
severe disease on the long term could not be determined. 
In addition, onychomycosis was clinically not suspec-
ted in any of our subjects with nail psoriasis; however, 
nails were not cultured to confirm its absence. Finally, 
although nail psoriasis proved to be relative stable over 
time in our population, a small percentage of children 
without nail psoriasis at baseline still developed nail 
abnormalities during follow up. This may lead to unde-
restimation of percentage of children with nail psoriasis 
used for longitudinal analysis. 
In conclusion, nail psoriasis in children is associated 
with more severe psoriasis cross-sectionally, as well as a 
more severe disease course over time. Our findings sug-
gest nail psoriasis to be a potential clinical predictor for a 
more severe disease course in the paediatric population. 
Therefore, nail psoriasis as a clinical predictor could 
assist in the prompt identification of patients at risk for 
a more severe disease course and subsequently result in 
early intervention to restrict further disease progression.
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